Patents Represented by Attorney Julie M. Lappin
-
Patent number: 8349381Abstract: An edible pet chew that is made of rehydrated hide about an inner fill via a positioning sheath.Type: GrantFiled: May 10, 2011Date of Patent: January 8, 2013Assignee: Societe des Produits Nestle S.A.Inventor: Christopher Alan Weinberg
-
Patent number: 7601727Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: July 27, 2007Date of Patent: October 13, 2009Assignee: Pfizer, Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7553972Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: February 9, 2007Date of Patent: June 30, 2009Assignee: Pfizer, Inc.Inventors: Mark A. Dombrowski, Allen J. Duplantier, Chakrapani Subramanyam
-
Patent number: 7432370Abstract: The present application discloses compounds of the formula wherein R2 and R3 are as defined herein. The present application further discloses certain pyrrolol[2,3-d]pyrimidine compounds having the 3R,4R stereochemical configuration shown above. Corresponding pharmaceutical compositions and methods for the treatment or prevention of a disorder or condition selected from organ transplant rejection, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases are also disclosed.Type: GrantFiled: June 15, 2004Date of Patent: October 7, 2008Assignee: Pfizer Inc.Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
-
Patent number: 7268133Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described hereinType: GrantFiled: April 12, 2004Date of Patent: September 11, 2007Assignee: Pfizer, Inc. Patent DepartmentInventors: David A. Griffith, Marlys Hammond
-
Patent number: 7259266Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.Type: GrantFiled: March 16, 2004Date of Patent: August 21, 2007Assignee: Pharmacia CorporationInventors: Jeffry Carter, David Brown, Li Xing, Karl Aston, John Springer, Francis Koszyk, Steven Kramer, Renee Huff, Yi Yu, Bruce Hamper, Subo Laio, Angela Deprow, Teresa Fletcher, E. Ann Hallinan, James Kiefer, David Limburg, Lijuan Wang, Cindy Ludwig, John McCall, John Talley
-
Patent number: 7247628Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein.Type: GrantFiled: November 4, 2003Date of Patent: July 24, 2007Assignees: Pfizer, Inc., Pfizer Products, Inc.Inventors: Robert L. Dow, Marlys Hammond
-
Patent number: 7232823Abstract: Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described hereinType: GrantFiled: May 25, 2004Date of Patent: June 19, 2007Assignee: Pfizer, Inc.Inventors: Philip A. Carpino, Subas M. Sakya
-
Patent number: 7183287Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: March 24, 2004Date of Patent: February 27, 2007Assignee: Pharmacia CorporationInventor: Richard C Durley
-
Patent number: 7153959Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.Type: GrantFiled: February 25, 2003Date of Patent: December 26, 2006Assignee: Pharmacia CorporationInventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu, Win Naing, Syaulan Yang
-
Patent number: 7138411Abstract: A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I? wherein X, A1, A2, A3, A4, R, R?, R1 and R2 are as described in the specification.Type: GrantFiled: November 22, 2002Date of Patent: November 21, 2006Assignee: G.D. Searle & Co.Inventors: Jeffery S Carter, Mark G Obukowicz, Balekudru Devadas, John J Talley, David L Brown, Matthew J Graneto, Stephen R Bertenshaw, Donald J Rogier, Jr., Srinivasan Raj Nagarajan, Cathleen E Hanau, Susan J Hartmann, Cindy L Ludwig, Suzanne Metz, Donald E Korte
-
Patent number: 7109211Abstract: A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I? wherein X, A1, A2, A3, A4, R, R?, R1 and R2 are as described in the specification.Type: GrantFiled: August 19, 2004Date of Patent: September 19, 2006Assignee: Pharmacia Corporation (of Pfizer, Inc.)Inventors: Jeffery S Carter, Mark G Obukowicz, Balekudru Devadas, John J Talley, David L Brown, Matthew J Graneto, Stephen R Bertenshaw, Donald J. Rogier, Jr., Srinivasan Raj Nagarajan, Cathleen E Hanau, Susan J Hartmann, Cindy L Ludwig, Suzanne Metz, Donald E Korte
-
Patent number: 7071198Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.Type: GrantFiled: May 5, 2004Date of Patent: July 4, 2006Assignee: Pharmacia CorporationInventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Ish K. Khanna, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Win Naing, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, John Walker, Richard M. Weier, Xiangdong Xu, Syaulan Yang, Yi Yu
-
Patent number: 7067540Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: February 14, 2003Date of Patent: June 27, 2006Assignee: Pharmacia CorporationInventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
-
Patent number: 7057049Abstract: This invention is directed generally to a process for making substituted pyrazoles, tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers. The substituted pyrazoles correspond in structure to Formula (I): wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification.Type: GrantFiled: April 1, 2003Date of Patent: June 6, 2006Assignee: Pharmacia CorporationInventors: Kimberley C. Allen, Dennis K. Anderson, John E. Baldus, Todd Boehlow, Jerry D. Clark, Dan R. Dukesherer, Albert D. Edney, Tom Fevig, Sastry Kunda, Jon P. Lawson, Patrick H. Lau, Lisa L. McDermott, Michael K. Mao, Jodi L. Moe, Partha Mudipalli, Win Naing, Shaun R. Selness, Christine B. Seymour, Tobin C. Schilke, Shekhar Viswanath, John K. Walker, Gopichand Yalamanchili
-
Patent number: 7056918Abstract: The present invention relates to novel triazolo-pyridines of the formula I wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R2 is selected from the group consisting of hydrogen, (C1–C6)alkyl or other suitable substituents; R3 is selected from the group consisting of hydrogen, (C1–C6)alkyl or other suitable substituents; s is an integer from 0–5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: March 11, 2002Date of Patent: June 6, 2006Assignee: Pfizer, Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Patent number: 7037923Abstract: The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: August 27, 2003Date of Patent: May 2, 2006Assignee: Pfizer, Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Patent number: 7019005Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I wherein R1, R2, Ar1 and HetAr2 are as described in the specification.Type: GrantFiled: June 6, 2003Date of Patent: March 28, 2006Assignee: G. D. Searle & Co.Inventors: Ashok S. Naraian, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
-
Patent number: 7005523Abstract: The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: August 27, 2003Date of Patent: February 28, 2006Assignee: Pfizer Inc.Inventors: Mark A. Dombroski, Michael A. Letavic, Kim F. McClure
-
Patent number: 6949652Abstract: The present invention relates to novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine to pharmaceutical compositions containing such crystal forms and to methods of treatment. 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is a potent inhibitor of MAP kinases, preferably p38 kinase (MAPK14/CSBP/RK kinase). 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.Type: GrantFiled: August 27, 2003Date of Patent: September 27, 2005Assignee: Pfizer, Inc.Inventors: Ming Kang, Zheng Jane Li, Zhengong Bryan Li, Yong Tao